Research fields

Synthesis Research Field

1999

Since the establishment of the research team on synthesis with the goal of substitution of import as well as expansion to overseas market, we have been actively developing synthetic technologies for raw pharmaceutical materials.

As a result,

In 1999, we successfully developed the synthesis technology for PPI (Proton Pump Inhibitor) including Lansoprazole, a therapeutic agent for peptic ulcer and reflux esophagitis, and started producing it in-house, replacing imports. In 2000, we launched and commercialized Clarithromycin, a macrolide antibiotics against Helicobacter Pylori. In 2001, we developed the synthesis technology for Allyamine, antifungal agent.

Based on the self-production technology for raw pharmaceutical materials, this has provided an opportunity to replace imports and further develop independent marketing strategies in the global market.

In the future,

We plan to continue our efforts in developing new synthesis technologies for competitive finished pharmaceutical products in the global market, and for optically active pharmaceuticals and intermediates, which are expected to have high market demand in the future.